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ABSTRACT 
Background: The use of complementary and alternative medicine for weight 
loss is becoming increasingly common worldwide. In overweight or obese pa- 
tients, this practice could be harmful. Available data concerning the use of com- 
plementary therapies and products (CTPs) for weight loss in these patients in 
Colombia are limited. 
Objectives: The aims of this study were to determine the prevalence of self- 
treatment with CTPs in overweight or obese patients in Colombia and to 
explore the relationship between CTP use and demographic, anthropometric, 
and biochemical parameters. 
Methods: This randomized, cross-sectional study was conducted at a regis- 
tered dieticians' office located at the Center for Nutritional Care, School of 
Nutrition and Dietetics, University of Antioquia, Medellin, Colombia, and at an 
outpatient clinic attended by a registered ietician located at the Pablo Tob6n 
Uribe Hospital, Medellin, Colombia. The study enrolled a random sample of 
overweight (body mass index [BMI], 25-30 kg/m 2) or obese (BMI, >30 kg/m 2) 
male and female patients aged 20 to 50 years received nutritional treatment in 
Colombia in 2002. Data concerning the use of weight4oss CTPs were gathered, 
and their possible association with demographic, anthropometric, and bio- 
chemical data was explored. 
Results: This randomized study comprised 94 patients (70 women, 24 men; 
mean [SD] age, 36.5 [9.7] years; mean [SD] BMI, 28.4 [4.2] kg/m2). Forty-nine 
(52.1%) patients reported self-treatment with weight-loss CTPs; 40 (42.6%) pa- 
tients used complementary products, and 21 (22.3%) used complementary 
therapies. Among the products, inadequately identified herbal medicines (ie, 
absence of available information concerning the composition of the products or 
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information could not be obtained from the patient [many of the products  used 
were not author ized for distr ibution in Colombia]), folkloric or home remedies, 
and commercia l  diets were most  commonly  used (40.0%, 40.0%, and 27.5%, 
respectively).  The use of CTPs was more prevalent in women compared  with 
men (P < 0.001; odds ratio [OR] = 6.43). In women, CTP use was significantly 
higher in patients with a higher educational level (P = 0.008; OR = 3.82) and in 
those who were single (P = 0.038; OR = 2.97). The use of CTPs was also more fre- 
quent in patients with a negative view of their current nutritional therapy (P = 
0.002; OR = 6.8). 
Conclusions: In the small group of overweight and obese patients in this 
study, 52.1% used CTPs. In obese women, those with a higher educational  level 
and/or  who were single were more likely to use CTPs. Patients were also more 
likely to use CTPs if they had a negative view of their current nutritional ther- 
apy. (Curr Ther Res Clin Exp. 2006;67:66-78) Copyright © 2006 Excerpta Medica, 
Inc. 
Key words: weight loss, herbal treatments,  obesity, complementary  medicine. 
INTRODUCTION 
The usage of complementary  and alternative medicine (CAM) in combinat ion 
with or instead of standard medical  care is high and continues to increase. One 
US study reported that the percentage of the populat ion using CAM increased 
from 33.8% to 42.1% between 1990 and 1997.1 Other US studies have reported 
CAM use ranging from 28.9% to 62.1%. 2-4 In 1 study of ambulatory  patients 
referred to an internist, the est imated proport ion of pat ients who had used 
CAM was 85.4%. 5In those studies, some of the reasons for using CAM reported 
by pat ients included maintaining ood health 5 and preventing or treating mus- 
culoskeletal condit ions, allergies, and other respi ratory problems.  1,4 Patients 
with cancer, 6 chronic disease (eg, diabetes mellitus), 7 and other severe dis- 
eases 5,8 have reported CAM use. Some patients use CAM in addit ion to conven- 
tional therapy. 1,2,4 Reasons pat ients have cited for supplemental  CAM use 
include discontent with medical  outcomes 4,8 and the percept ion that CAM is 
harmless.4,9,10 
CAM use is highest in pat ients who are female, are nonsmokers,  are physi- 
cally active, have a normal  body mass index (BMI), and/or  eat low-fat diets with 
a high fruit and vegetable content, u Individuals aged 35 to 54 years with a high 
level of educat ion and above-average incomes have been found to use CAM 
more frequently compared  with the general population. 1-4,6,12 Women most  
commonly  cite maintenance of a healthy body  and mind 2,4 and weight reduc- 
tion 12,13 as reasons for CAM use. 
Obesity, a common chronic condit ion that continues to increase in preva- 
lence (-1.1 billion adults worldwide are classified as overweight or obese),  14 is 
associated with a decreased life span, 15 and contr ibutes to morbid i ty  and mor- 
tality from a var iety of secondary  chronic condit ions. 16,17 
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The combination of caloric restriction, increased physical activity, and be- 
havioral therapy might be an effective approach to obesity. 18 However, some 
patients might require pharmacotherapy or other strategies to reach their thera- 
peutic goals) 8,19 In a meta-analysis 2° of 79 clinical trials of diet plus pharmaco- 
therapy (sibutramine, orlistat, fluoxetine, sertraline, bupropion, topiramate, 
or zonisamide) for obesity, the mean weight loss was found to be 10 kg at 1 year. 
However, such outcomes frequently do not meet patients' expectations, espe- 
cially in those with the highest pretreatment weights. 21 This difference between 
expectations and outcomes might lead to patients having negative perceptions 
of their weight-loss therapy and a lack of motivation to adhere to the therapy. 12 
As a result, patients might use CAM (in combination with conventional medical 
care), involving the use of diet and/or medicines plus complementary therapies 
and products (CTPs) for weight loss. 22-31 Most often, CTPs are used without he 
knowledge of a health care professional, u,22 There is little evidence of the effi- 
cacy of CTPs, 23,24,28 and their association with adverse vents is a concern. 1°,22'28 
Information concerning the prevalence and anthropometric and biochemical 
parameters associated with the use of CTPs for weight loss in overweight or 
obese patients is limited. The objectives of this study in overweight or obese 
patients receiving nutritional treatment were to determine the prevalence of 
self-treatment with CTPs and to explore the relationship between CTP use and 
demographic, anthropometric, and biochemical parameters. 
PATIENTS AND METHODS 
This randomized, cross-sectional study was conducted at a registered ieti- 
cian's office located at the Center for Nutritional Care, School of Nutrition and 
Dietetics, University of Antioquia, Medellin, Colombia, and at an outpatient 
clinic attended by a registered ietician located at the Pablo Tob6n Uribe 
Hospital, Medellin, Colombia. The study protocol was approved by the respec- 
tive institutional review board. 
Inclusion and Exclusion Criteria 
Overweight (BMI, 25-30 kg/m 2) or obese (BMI, >30 kg/m 2) male and female 
patients aged 20 to 50 years who were receiving ambulatory nutritional treat- 
ment during 2002 were eligible for the study. Nutritional treatment comprised a 
low-calorie diet (500 kcal/d less than the total energy intake required to main- 
tain body weight). The diet provided 30% of energy from fat, 55% from carbohy- 
drates, and 15% from protein. Exercise (->30 minutes 4 times a week) was also 
recommended to patients. Patients with cardiovascular disease, those receiv- 
ing nutritional treatment other than a calorie-restricted diet, and pregnant or 
breastfeeding women were excluded. Patients who prayed for health reasons 
were also excluded from the study. 
The files of patients who met the inclusion criteria based on their medical 
records were numbered from 1 to 312 consecutively. Using Epi-Info version 
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6.04b (Centers for Disease Control and Prevention, Atlanta, Georgia), a list of 
random numbers was obtained. Patients whose file number coincided with the 
random numbers were invited to participate. Written informed voluntary con- 
sent was obtained from all of the patients who were enrolled in the study. 
Methods 
The primary end point was the prevalence of self-treatment with CTPs in 
overweight or obese patients receiving nutritional treatment, and the second- 
ary end points were the relationships between CTP use and demographic, an- 
thropometric, and biochemical parameters. 
During a clinic visit, the prevalence of self-treatment with CTPs in combina- 
tion with conventional nutritional treatment, along with demographic, anthro- 
pometric, and biochemical parameters were gathered by 2 dieticians, 1 bac- 
teriologist, or 2 students of nutritional therapy trained in collecting such 
information. Also at the clinic visit, patients verified that they had not ingested 
food, beverages, or diuretics for a minimum of 12 hours before the visit and that 
they had not engaged in intense physical activity or ingested fatty foods in the 
24 hours before the visit. 
To determine the use of self-treatment with CTPs in combination with conven- 
tional nutritional treatment, patients were asked several questions. First, they 
were asked whether they had ever self-administered complementary therapies 
for weight loss during the past year. The patients who answered yes were then 
asked to specify which of the following therapies they had used: massage, bioen- 
ergy, acupuncture, lectrostimulation, chiropractic, or other. They were also 
asked whether they had ever self-administered complementary products for 
weight loss during the past year. Patients who answered yes were asked to spec- 
ify the type of product used---commercial diet (diets different from those of the 
nutritional treatment), folkloric or home remedies (infusions or boiled prepara- 
tions of medicinal plants or food products), herbal medicines (medicinal plants 
prepared in a dosing formulation and adequately or inadequately identified), or 
homeopathic medicine (any composition and infinitesimal dose). 1-7,11 
To determine patients' satisfaction with their weight loss and nutritional 
treatment, patients were asked: "How would you qualify the weight loss 
reached uring the nutritional treatment?" and "How would you qualify your 
satisfaction with the received nutritional treatment?" Answers were rated on a 
6-point scale (0 = extremely unsatisfactory to 5 = very satisfactory). 
Anthropometric Data 
The anthropometric data were measured with excess clothing and materials 
removed. Weight was measured using a standard electronic scale (Platform 
Scale, A&D Co. Ltd., Phoenix, Arizona) with a capacity of 150 kg and accuracy 
_+0.05 kg. Height was measured using a standard ruler that could be used to 
measure up to 220 cm with an accuracy _+0.1 cm. Waist circumference (WC) and 
hip circumference were measured using a fiberglass tape measure (Mabis, 
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Tokyo, Japan) with an accuracy _+0.1 cm. The mean of 2 measurements of weight 
and height were used. Using Quantum II (RJL Systems, Clinton Township, 
Michigan) the percentage of fat weight (%FW) was determined using the bio- 
electrical impedance technique with 4 electrodes. 
BMI was classified as follows: low weight, <18.5 kg/m2; normal weight, 
18.5-24.9 kg/m2; overweight, 25.0-29.9 kg/m2; and obese, >30.0 kg/m 2. Waist/hip 
ratio (WHR) >0.9 in men and >0.85 in women was considered higher risk. WC 
>102 cm in men and >89 cm in women was considered higher isk. In men, %FW 
was classified as follows: thin, <12%; appropriate, 12% to 15%; acceptable, >15% 
to 20%; and excessive, >20%. In women, %FW was classified as follows: thin, 
<15%; appropriate, 15% to 20%; acceptable, >20% to 25%; and excessive, >25%. 18 
Patients enrolled in the study received individual care by a registered ieti- 
cian concerning diet for healthy adults, as recommended by National Task 
Force on the Prevention and Treatment of Obesity14; and the dietician encouraged 
each patient o consume a nutritionally balanced, low-calorie diet (500 kcal/d 
less than the total energy intake required to maintain body weight) and some 
meal plans and daily menu options were provided. 
Biochemistry 
Personnel from the Bacteriology Laboratory, University of Antioquia, 
Medellin, Colombia, collected blood samples and performed the analyses. 
Because the patients did not have established cardiovascular disease (primary 
prevention), levels of fasting plasma glucose, 70 to 109 mg/dL; total cholesterol 
(TC), _<239 mg/dL; low-density lipoprotein cholesterol, _<129 mg/dL; high-density 
lipoprotein cholesterol, a40 mg/dL; and triglycerides, _<149 mg/dL were consid- 
ered normal. 32 
Statistical Analysis 
Statistical analysis was performed using SPSS version 10 (SPSS Inc., Chicago, 
Illinois). Data are reported as mean (SD). The ~2 test was used to compare pro- 
portions, and the Student test was used to compare means, including odds 
ratios (ORs) and 95% CIs. Comparisons were analyzed using a 2-tailed test. P < 
0.05 was considered statistically significant. The Fisher exact test was used to 
compare categories that had <5 data sets. 
RESULTS 
One hundred five patients were selected; 94 agreed to participate and com- 
pleted the study (70 women, 24 men; mean [SD] age, 36.5 [9.7] years; mean [SD] 
BMI, 28.4 [4.2] kg/m2; mean [SD] time after beginning of nutritional treatment, 
13.1 [3.0] months). Eleven patients did not attend the session in which data 
were collected, for a variety of reasons, most of which were related to time 
restrictions. Demographic and baseline clinical characteristics of and CTPs use 
by the patients are shown in Table I. 
70 
P. Amariles et aL 
Table I. Demographic and clinical characteristics of the study patients. 1 
Did Not Use 
Used CTPs CTPs All Patients 
Characteristic (n = 49) (n = 45) (N = 94) 
Age group, no. (%) 
<38 y 27 (55.1) 21 (46.7) 48 (51.1) 
>38 y 22 (44.9) 24 (53.3) 46 (48.9) 
Sex, no. (%) 
Female 44 (89.8) 2 26 (57.8) 70 (74.5) 
Male 5 (10.2) 19 (42.2) 24 (25.5) 
Socioeconomic status, no. (%) 
Low-medium 36 (73.5) 36 (80.0) 72 (76.6) 
Medium-high 13 (26.5) 9 (20.0) 22 (23.4) 
Educational level, no. (%) 
<Primary school 11 (22.4) 18 (40.0) 29 (30.9) 
~Secondary school 38 (77.6) 27 (60.0) 65 (69.1) 
Marital status, no. (%) 
Single 25 (51.0) 17 (37.8) 42 (44.7) 
Married 24 (49.0) 28 (62.2) 52 (55.3) 
Physical activity, no. (%) 
Never or rarely 20 (40.8) 22 (48.9) 42 (44.7) 
Regularly 29 (59.2) 23 (51.1) 52 (55.3) 
Associated pathology, no. (%) 
Yes 3 19 (38.8) 19 (42.2) 38 (40.4) 
No 30 (61.2) 26 (57.8) 56 (59.6) 
Satisfied with weight loss, no. (%) 
Yes 18 (36.7) 30 (66.7) 48 (51.1) 
No 31 (63.3) 4 15 (33.3) 46 (48.9) 
Satisfied with nutritional treatment, no. (%) 
Yes 33 (67.3) 42 (93.3) 75 (79.8) 
No 16 (32.7) 5 3 (6.7) 19 (20.2) 
Consumed fruits and vegetables, no. (%) 
Yes 34 (69.4) 30 (66.7) 64 (68.1) 
No 15 (30.6) 15 (33.3) 30 (31.9) 
Anthropometric variables, mean (SD) 
Weight, kg 70.8 (I 3.6) 74.7 (9.9) 72.2 (I 7.2) 
BMI, kglm 2 28.2 (4.6) 28.7 (3.9) 28.4 (4.2) 
%FW 38.3 (7.3) 6 34.3 (I 1.4) 36.3 (9.6) 
WC, cm 83.7 (11.1) z 88.8 (8.5) 86.1 (10.2) 
HC, cm 102.5 (8.4) 102.6 (7.0) 102.5 (7.7) 
WHR 0.81 (0.07) 8 0.87 (0.08) 0.83 (0.08) 
(continued) 
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Table I. (Cont inued)  
Did Not  Use 
Used CTPs CTPs All Patients 
Characteristic (n = 49) (n = 45) (N = 94) 
Biochemical variables, mean (SD), mg/dL  
FPG 82.2 (10.6) 85.2 (22.4) 83.6 (1 7.2) 
TC 193.4 (43.0) 9 215.6 (50.0) 204.0 (47.6) 
HDL-C 44.5 (9.7) 45.0 (14.0) 44.7 (11.9) 
LDL-C 120.8 (37.6) 133.6 (35.9) 127.5 (36.7) 
TG 140.3 (80.6) 171.7 (157.8) 155.3 (123.5) 
CTPs = complementary therapies or products; BMI = body mass index; %FW = percentage of fat 
weight; WC = waist circumference; HC = hip circumference; WHR = waist/hip ratio; FPG = fasting 
plasma glucose; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low- 
density lipoprotein cholesterol; TG = triglycerides. 
1Percentages might not total 100% due to rounding. 
2p < 0.001 versus men (odds ratio [OR] = 6.43; 95% CI, 1.97-24.23). 
3Includes hypertension, dyslipidemia, depression, anxiety, and back and/or joint pain. 
4p = 0.004 versus no CTP (OR = 3.44; 95% CI, 1.47-8.05). 
sp = 0.002 versus no CTP (OR = 6.8; 95% CI, 1.8-25.3). 
6p = 0.044 versus no CTR 
7p = 0.014 versus no CTR 
8p = 0.002 versus no CTP (OR = 0.245; 9.5% CI, 0.99-0.608). 
9p = 0.023 versus no CTP. 
Use of Complementary Therapies and Products 
Forty-nine (52.1%) patients responded that they had used weight-loss CTPs by 
self-treatment i  addition to nutritional treatment. Specifically, 40 (42.6%) patients 
used complementary products, and 21 (22.3%) used complementary therapies 
(Table II). Some patients reported using as many as 3 weight-loss CTPs. 
Among the products, inadequately identified herbal medicines, folkloric or 
home remedies, and commercial diets were the most commonly used alterna- 
tives (16 [40.0%], 16 [40.0%], and 11 [27.5%], respectively) (Table liD. The folk- 
loric or home remedies (n = 16) identified were Ocimum basilicum (basil) (3 
[18.8%] patients), Apium graveolens (celery) (2 [12.5%]), Citrus aurantium (bit- 
ter orange) leaves (2 [12.5%]), Taraxacum officinale (dandelion) (1 [6.3%]), 
Citrus decumana (grapefruit) (2 [12.5%]), Allium cepa (onion) (1 [6.3%]), Allium 
sativum (garlic) (1 [6.3%]), Medicago sativa (alfalfa) (1 [6.3%]), Avena sativa 
(oatmeal) (1 [6.3%]), Triticum aestivum (wheat germ) (1 [6.3%]), and Chayota 
edulis (chayote) (1 [6.3%]). 
The complementary therapies most often used were massage (6 [28.6%] pa- 
tients), bioenergy (5 [23.8%]), and acupuncture (4 [19.0%]); smaller percentages of 
the patients used electrostimulation a d acupuncture (2 [9.5%]), chiropractic 
and acupuncture (2 [9.5%]), electrostimulation and bioenergy (1 [4.8%]), auricular 
plaster therapy (weight-loss girdles) (1 [4.8%]), and chiropractic (1 [4.8%]). 
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Table II. Complementary therapies and products (CTPs) used by pa- 
tients in self-treatment for weight loss (N = 49). 
CTP No. (%) 
Complementary product alone* 28 (59.2) 
Complementary therapy t and product* 12 (24.5) 
Complementary therapy alone t 9 (18.4) 
*Folkloric or home remedy, herbal medicine, homeopathic product, or commercial 
diet. 
tMassage, bioenergy, acupuncture, electrostimulation, chiropractic, or auricular 
plaster therapy (weight-loss girdles). 
Demographic  Variables and Complementary  Therapy and Product Use 
Demographic data are presented in Table I. A significantly higher proport ion 
of women reported using CTPs compared with men (44 [89.8%] vs 5 [10.2%]; 
P < 0.001; OR = 6.43 [95% CI, 1.97-24.23]). In women, CTP use was significantly 
more frequent in those having a high educational level compared with a lower 
level (34 [73.9%] vs 12 [26.1%]; P = 0.008; OR = 3.82 [95% CI, 1.23-12.62]) and 
those who were single compared with those who were married (28 [63.6%] vs 
16 [36.4%]; P = 0.038; OR = 2.97 [95% CI, 1.04-8.49]). 
In the overall study population, no significant differences in age, marital status, 
socioeconomic status, physical activity, associated morbidity, or educational 
level were found between the patients who used CTPs and those who did not. 
Table III. Complementary products used by patients in self-treatment for weight loss 
(N = 40). 
Complementary Product No. (%) 
Herbal medicine* 10 (25.0) 
Folkloric or home remedy 11 (27.5) 
Commercial diet 7 (17.5) 
Folkloric or home remedy and commercial diet 2 (5.0) 
Herbal medicine* and commercial diet 2 (5.0) 
Herbal medicine* and folkloric or home remedy 2 (5.0) 
Marrubium vulgare (horehound) 2 (5.0) 
Herbal medicine,* Acacia saligna (mimosa), and folkloric or home remedy 1 (2.5) 
Herbal medicine,* Theaceae sinensis (green tea), and homeopathic product 1 (2.5) 
Homeopathic product 1 (2.5) 
Quercus coccifera (kermes oak) 1 (2.5) 
*Inadequately identified (absence of available information concerning composition, or information 
could not be obtained from the patients). 
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A significantly higher proportion of patients who used CTPs indicated issat- 
isfaction with their weight loss or nutritional treatment compared with non- 
users (weight loss: 31/49 [63.3%] vs 15/45 [33.3%] patients; P = 0.004; OR = 3.44 
[95% CI, 1.47-8.05]; nutritional treatment: 16 [32.7%] vs 3 [6.7%] patients; P = 
0.002; OR = 6.8 [95% CI, 1.8-25.3]). 
Anthropometric Variables and Complementary Therapy 
and Product Use 
The anthropometric data are presented in Table I. The mean (SD) %FW was 
significantly larger in those who used CTPs compared with those who did not 
(38.3% [7.3%] vs 34.3% [11.4%]; P= 0.044), whereas mean (SD) WC (83.7 [11.1] vs 
88.8 [8.5] cm; P = 0.014) and WHR (0.81 [0.07] vs 0.87 [0.08]; P = 0.002; OR = 0.245 
[95% CI, 0.099-0.608]) were significantly smaller in CTP users than nonusers. 
Biochemical Variables and Complementary Therapy and Product Use 
For biochemical variables measured, the only statistically significant difference 
between the CTP users and nonusers was in mean (SD) TC level (193.4 [43.0] mg/dL 
vs 215.6 [50.0] mg/dL; P = 0.023) (Table I). No association was found between any 
of the biochemical variables and CTP use or nonuse. 
DISCUSSION 
The findings of this study suggest that >50% of overweight and obese patients 
receiving nutritional treatment use CTPs by self-treatment. 
In a previous study, Blanck et a122 found that only 7% of 14,679 male and 
female outpatients were self-treating with CTPs. The low rate found in that 
study compared with that in the present study (52.1%) might have been due 
to the facts that (1) Blanck et a122 did not investigate the use of therapies; and 
(2) the study by Blanck et a122 was carried out in the general population (in 
obese women in that study, the prevalence was 28.4%). 
The present study found an association between the use of weight-loss CTPs 
and a lack of satisfaction with nutritional treatment. This finding was similar to 
that from a recent study of CAM use the United States, 4 in which 27.7% of CAM 
users indicated that they believed that the conventional treatments they re- 
ceived were not effective. 4 Similarly, a telephone survey in 232 patients with 
rheumatoid arthritis found that 50% of patients used complementary therapies 
because they thought their conventional medication was ineffective. 8 This 
result differs from those from a previous tudy, 9in which data did not support 
the hypothesis that CAM use in the United States is due to dissatisfaction with 
conventional treatment. 
Factors that might be associated with the frequent use of CTPs in overweight 
and obese patients are the notable increase in CTP use (mainly herbal or nutri- 
tional supplements, folkloric remedies, massage, multivitamins, and self-care 
groups) in the general population, 14,8 the availability and accessibility of these 
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products, 22 the low rate of fulfillment of the objectives of the nutritional treat- 
ment, the discrepancy between the expectations of the patients and the results 
achieved, and the difficulty in maintaining lifestyle changes. 12,21,23,26 
In the present study, the use of weight-loss complementary products (42.6%) 
was similar to that of herbal and nutritional supplements (33%) found by 
Gunther et a111 in a study of 61,587 participants aged 50 to 76 years who com- 
pleted a self-administered questionnaire. 
However, the use of herbal medicines that are not authorized in Colombia for 
the treatment of weight loss and/or that have fictitious product names have 
been important obstacles in determining the composition, effectiveness, and 
tolerability of these products. 28-33 The inability to study herbal medicines for 
these reasons, and the possibility of serious adverse vents due to drug inter- 
actions, 34 might present important health risks regardless of the possible bene- 
ficial effects of these products on weight l oss .  29-31 Such adverse events have 
occurred with chromium salts, ephedra and ephedrine, 35caffeine and other 
zantic bases, 23,36 and usnic acid. 37 In addition, the possibility of adulteration of
CTPs with other substances and the fact that the sale of some CTPs has been 
prohibited in Colombia for several years might also lead to health risks. 38,39 
However, in this study, we did not ask about adverse drug events. 
Among the folkloric or home remedies patients reported using in our study, 
only C aurantium, 3°C decumana, nd T officinale have been assessed in relation 
to the indications and have been recommended for the treatment of obesity. 24 
This situation is similar to that in herbal medicines, of which only Marrubium 
vulgare (horehound) and Camellia sinensis (green tea) have been evaluated in 
relation to the indications and have been recommended for the treatment of 
obesity. 24 This finding shows the need to educate patients about the possible 
benefits of CTPs in the treatment of obesity. 
As in other studies in the general population in the United States, 1,4 in patients 
who were consulting an internist, we found that women used CTPs more fre- 
quently compared with men. 5 The rate of CTP use in obese women in our study 
was 59.6%, and, as in other studies of the use of weight-loss products 22 or herbal 
or nutritional preparations, 11 in women who used CTPs, those with a higher edu- 
cational level used these products ignificantly more frequently compared with 
women with less education. 1-8,11 This finding is related to a concern in this group 
to be healthy, 34,11 with emphasis on appearance and body weight. 13 In women, 
there was no clear explanation for the finding of the association between CTP 
use and being single. This topic could be researched in future studies. 
With the exception of the WHR, no statistically significant associations were 
found between anthropometric indicators and CTP use. Several reviews assess- 
ing the effects of CTPs in the treatment ofobesity found significant improvements 
in WC and WHR in patients who used CTPs, but concluded that more and better 
evidence of the benefits of these products 22,23,28 or therapies 27was needed. 
In the present study, the fact that the %FW was higher in CTP users suggests 
that these products might affect the distribution of corporal fat, which might 
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mean associated health risks. 15,32 This fat should be examined in a prospective, 
longitudinal study designed to compare the efficacy and tolerability of nutri- 
tional treatment plus CTPs versus nutritional treatment alone. 
The finding in our study that patients who used CTPs had significantly lower 
TC levels compared with patients who did not use CTPs might have been the 
result of better habits and healthier lifestyles in CAM users. 11,13 
Health care professionals should investigate and analyze the benefits and 
risks of CTP use and document their findings in detail. Studies designed to deter- 
mine the benefits and risks associated with CTP use in overweight and obese 
patients are needed. 
Study Limitations 
Because this study had several limitations, the results must be interpreted with 
caution. First, because this was a cross-sectional study with a small number of 
patients, causal associations could not be established. Such relationships could 
help to document the effectiveness or lack of effectiveness of the use of weight-loss 
CTPs. Second, some patients did not adequately identify the type of product hat 
they were using, which reflected potential recall bias and limited a detailed review 
of potential benefits and risks of CTP use. Third, multiple statistical analyses were 
conducted in a small number of patients in the study. In addition, the exclusion of 
an analysis of prayer for health might have resulted in an underestimation f the 
percentage ofpatients who used CAM. Finally, adverse vents were not recorded. 
CONCLUSIONS 
In the small group of overweight and obese patients in this study, 52.1% used 
CTPs. In obese women, those with a higher educational level and/or who were 
single were more likely to use CTPs. Patients were also more likely to use CTPs 
if they had a negative view of their current nutritional therapy. 
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